Identifying pathogenic proteins leads to potential new treatments for diseases such as diabetes.

Published Date: 02 Mar 2023

New research has identified hundreds of proteins that can lead to the development of metabolic diseases, such as type 2 diabetes mellitus, and therefore have treatment potential.

Read Full News

Latest News

Early Use Of Novocure's Brain Cancer Therapy Shows no Significant Survival Benefit in Late-stage Trial

Novocure said on Thursday that a late-stage trial showed early use of its non-invasive cancer therapy ⁠did not significantly improve overall survival in patients with newly...

GLP-1s Could Help Improve Symptoms of PMOS

The metabolic symptoms of PMOS, including overweight and diabetes, may be effectively treated by GLP-1s.

Medicine Shortages Among Worst Ever Seen, Pharmacists Warn

Health leaders are calling for an emergency taskforce as record-breaking shortages hit patients and stretch pharmacies to the limit.

Tirzepatide Tops Semaglutide in Real-World Weight Loss

Tirzepatide leads to greater and faster weight loss than semaglutide in a real-world analysis of more than 20,000 patients with obesity.

Are GLP-1s Increasing Eating Disorder Risk?

With GLP-1s readily available, some experts fear misuse is increasing and may be fueling eating disorders. Physicians describe what they are seeing and how they manage the risks.

US FDA Sends 25 Letters to Telehealth Companies Over Claims on Compounded Weight-loss Drugs

The U.S. Food and Drug Administration issued 25 warning letters to telehealth companies for marketing false and misleading claims about ⁠compounded versions of Eli Lilly and...

Todays Updates

Timely ‘Nudges’ Help Spur Talks on Patient Care Goals

Simple well-timed prompts to clinicians and patients with advanced cancer can increase conversations around care goals, but clear documentation remains a challenge.

Todays Updates

Timely ‘Nudges’ Help Spur Talks on Patient Care Goals

Simple well-timed prompts to clinicians and patients with advanced cancer can increase conversations around care goals, but clear documentation remains a challenge.

Latest News

Novocure said on Thursday that a late-stage trial showed early use of its non-invasive cancer therapy ⁠did not significantly improve overall survival in patients with newly...

The metabolic symptoms of PMOS, including overweight and diabetes, may be effectively treated by GLP-1s.

Health leaders are calling for an emergency taskforce as record-breaking shortages hit patients and stretch pharmacies to the limit.

Tirzepatide leads to greater and faster weight loss than semaglutide in a real-world analysis of more than 20,000 patients with obesity.

With GLP-1s readily available, some experts fear misuse is increasing and may be fueling eating disorders. Physicians describe what they are seeing and how they manage the risks.

The U.S. Food and Drug Administration issued 25 warning letters to telehealth companies for marketing false and misleading claims about ⁠compounded versions of Eli Lilly and...

News All Time

GLP-1s Aren’t a Solo Act. They Need Comprehensive Planning

Lifestyle changes, tracking, and support should go hand-in-hand with weight loss drugs.

AI Eye Scan Cuts Unneeded Diabetes Macular Edema Referrals

An AI-based OCT system integrated into standard diabetic retinopathy screening pathways reduces unwarranted referrals for diabetic macular edema, a recent study shows.

Neumora Scraps Depression Drug Development After Repeated Trial Failures

Neumora Therapeutics will abandon the development of its experimental depression drug following the latest trial failures and ⁠said it would cut 35% of its workforce,...

Chronic Opioid Use Raises Risk for Endocrinopathies

Possible complications include adrenal insufficiency, hypogonadism, hyperprolactinemia, hospitalization, and mortality.

Teplizumab Approved for Pediatric Stage 3 Type 1 Diabetes

The drug was previously approved for stage 2 T1D.

Encaleret Shows Rapid Response in ADH1

The oral modulator of the calcium-sensing receptor targets the causes of ADH1, significantly improving serum and urine calcium levels.

Testosterone Prescribing Often Ignores Guidelines

Only 12% of patients prescribed testosterone underwent appropriate diagnostic testing, and overprescribing was common in a single-center US study.

Palopegteriparatide Benefits Sustained Beyond 3 Years

Final results from the PaTHway trial show the long-acting parathyroid hormone therapy enabled patients with hypoparathyroidism to achieve independence from high-dose calcium and vitamin D supplements.

One in Four Teen Girls and Young Women at Risk for PMOS

Findings suggest young females should be assessed and, if at risk, monitored.

Novo Nordisk Flags Patient Data Breach From Some Clinical Trials in Cyberattack

Novo Nordisk said on Thursday it has identified a security incident in which certain information, including ⁠patient data from some clinical trials, was copied externally...

Tirzepatide Outperforms Conventional Care in Early Diabetes

Tirzepatide offered better glycemic control and greater weight loss than intensive conventional care in adults with early type 2 diabetes, a study finds.

AI-Guided Prep Improves Bariatric Surgery Consults

A structured, AI-supported metacognitive framework substantially enhances the quality of metabolic and bariatric surgery consultations.

PMOS: Insulin Resistance Affects Fertility and Pregnancy

Prepregnancy insulin resistance is associated with impaired fertility and increased pregnancy complications such as preeclampsia.

Over-the-Counter CGM Okayed for Kids

The US FDA extended the age of use for Dexcom’s Stelo down to 2 years.

Novel Oral GLP-1 Shows A1c and Weight-Loss Benefits

The new drug would add another oral GLP-1 with no fasting or fluid intake restrictions to clinicians’ toolboxes, improving options for targeted treatment.